Art. -Nr.: HY-B0593A

Ceftazidime pentahydrate

(Synonyms: GR20263 pentahydrate)

46 Cited Publications

Kundenbewertung

Based on 46 publication(s) in Google Scholar

Ceftazidime (GR20263) pentahydrate , an antibiotic, has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime pentahydrate is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 78439-06-2
Formel: C₂₂H₃₂N₆O₁₂S₂
Molecular Weight:636.65

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ceftazidime pentahydrate Chemical Structure

CAS. Nr.: 78439-06-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (46)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

β-lactam

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

In Vitro

Ceftazidime (0-8 μg/mL approximately, 24 h) pentahydrate displays antibacterial and anti-biofilm activities against P. aeruginosa strains^[2].
Ceftazidime (0-40 μg/mL approximately, 18-20 h) pentahydrate has inhibitory activities against S. maltophilia isolates^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

P. aeruginosa strains (PAO1, PA1, PA2)
Concentration:

0-8 µg/mL approximately
Incubation Time:

24 h
Result:

Displayed antibacterial and anti-biofilm activities with MIC values of 2-4 µg/mL.

In Vivo

Ceftazidime (2 h infusion of injection, 2 000 mg, every 8 h for 24 h) pentahydrate moderately reduces bacterial density in a murine thigh infection model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Murine thigh infection model^[4]
Dosage:

2000 mg
Administration:

2 h infusion of injection, every 8 h for 24 h.
Result:

Reduced bacterial density against the isogenic NDM (New Delhi metallo-β-lactamase) strain.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 78439-06-2
Appearance Solid
Molecular Weight 636.65
Formel C₂₂H₃₂N₆O₁₂S₂
Color White to off-white
SMILES

O=C1[C@@H](NC(/C(C2=CSC(N)=N2)=N\OC(C)(C(O)=O)C)=O)[C@@]3([H])SCC(C[N+]4=CC=CC=C4)=C(C([O-])=O)N13.[5H2O]
Synonyms

GR20263 pentahydrate
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (46)

All Microbiological AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Bioact Mater

Melatonin-incorporated brain extracellular matrix hydrogel enhances NSCs mitochondrial metabolism to promote neuroregeneration via the AMPK-PGC-1α-NRF1/TFAM axis after spinal cord injury. [Abstract]

2026 Apr 9:63:373-389. PMID: 42006003
Nat Commun

Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]

2022 Mar 2;13(1):1116. PMID: 35236849
J Clin Invest

SARS-CoV-2 antibody-dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors. [Abstract]

2026 Feb 23;11(4):e197773. PMID: 41729079
Adv Sci (Weinh)

A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. [Abstract]

2020 Jul 21;7(17):2001374. PMID: 32995131
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
NPJ Biofilms Microbiomes

Echinacoside reduces intracellular c-di-GMP levels and potentiates tobramycin activity against Pseudomonas aeruginosa biofilm aggregates. [Abstract]

2025 Mar 7;11(1):40. PMID: 40055321
NPJ Biofilms Microbiomes

Gut microbiota dysbiosis-mediated ceramides elevation contributes to corticosterone-induced depression by impairing mitochondrial function. [Abstract]

2024 Oct 28;10(1):111. PMID: 39468065
Pharmaceutics

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. [Abstract]

2023 Nov 30;15(12):2705. PMID: 38140046
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Mol Syst Biol

Impact of drugs and environmental contaminants on amine production by gut bacteria. [Abstract]

2025 Jun 30. PMID: 40588570

Ceftazidime pentahydrate purchased from MedChemExpress. Usage Cited in: Mol Syst Biol. 2025 Jun 30. [Abstract]

Growth and cadaverine production dynamics in E. coli treated with 20 µM of Ceftazidime. Treated cultures show a brief period where the optical density (Absorbance, 595 nm) increases, concurrent with a burst of cadaverine production far above untreated levels. This indicates that this β-lactam antibiotic does not immediately kill the cells but allows for a brief period of growth and stress-induced polyamine production prior to bacterial cell lysis. Lines indicate the mean, and shaded areas the standard deviation of n = 6 biological replicates.
BMC Microbiol

Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China. [Abstract]

2020 Jun 29;20(1):187. PMID: 32600252
Molecules

Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]

2025 Mar 9;30(6):1224. PMID: 40142001
Int J Antimicrob Agents

Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]

2025 Oct;66(4):107551. PMID: 40499596
Int J Antimicrob Agents

In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022. [Abstract]

2025 Sep;66(3):107550. PMID: 40480535
Int J Antimicrob Agents

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]

2018 Aug;52(2):269-271. PMID: 29559273
Sci Rep

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. [Abstract]

2022 Oct 7;12(1):16814. PMID: 36207358
Microorganisms

Antimicrobial Resistance and Genomic Characteristics of Escherichia coli Strains Isolated from the Poultry Industry in Henan Province, China. [Abstract]

2024 Mar 13;12(3):575. PMID: 38543626

Ceftazidime pentahydrate purchased from MedChemExpress. Usage Cited in: Microorganisms. 2024 Mar 13;12(3):575. [Abstract]

Percentages of E. coli strains showing antimicrobial resistance to different antimicrobial agents. AMP, Ampicillin; CAZ, Ceftazidime; IPM, Imipenem; MRP, Meropenem; GEN, Gentamicin; OFX, Ofloxacin; SXT, Trimethoprim–sulfamethoxazole; TET, Tetracycline; TGC, Tigecycline; CL, Colistin; FFC, Florfenicol.
Antimicrob Agents Chemother

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. [Abstract]

2026 Mar 23:e0186025. PMID: 41870042
Antimicrob Agents Chemother

PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate. [Abstract]

2025 May 7;69(5):e0179724. PMID: 40227072
Antimicrob Agents Chemother

Prediction of higher ceftazidime-avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis. [Abstract]

2025 Mar 5;69(3):e0151824. PMID: 39912660
Antimicrob Agents Chemother

An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates. [Abstract]

2023 Oct 18;67(10):e0030123. PMID: 37681977
Antimicrob Agents Chemother

Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. [Abstract]

2018 Jul 27;62(8):e00414-18. PMID: 29760136
J Antimicrob Chemother

Harnessing metabolic dependence-driven antibiotic synergy to eradicate tolerant Pseudomonas aeruginosa. [Abstract]

2026 Jun 3;81(7):dkag204. PMID: 42267541
J Antimicrob Chemother

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]

2026 Feb 2;81(3):dkag034. PMID: 41648989
J Antimicrob Chemother

Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies. [Abstract]

2026 Jan 19;81(2):dkaf495. PMID: 41549665
J Antimicrob Chemother

Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]

2025 Nov 5:dkaf408. PMID: 41206063
Microbiol Spectr

In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients. [Abstract]

2023 Dec 12;11(6):e0304723. PMID: 37982634
J Antimicrob Chemother

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. [Abstract]

2023 Apr 3;78(4):983-990. PMID: 36775993
J Antimicrob Chemother

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. [Abstract]

2022 Sep 30;77(10):2803-2808. PMID: 35848936

Ceftazidime pentahydrate purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2022 Sep 30;77(10):2803-2808. [Abstract]

In vivo change in log10 cfu/thigh of each isolate treated with saline control, Ceftazidime 2 g IV q8h 2 h infusion HSR, Ceftazidime/Avibactam 2.5 g q8h 2 h infusion HSR or meropenem 2 g q8h 3 h infusion HSR for three P. aeruginosa with inserted GES β-lactamases. (a) PSA 2136, with inserted GES-1 (ESBL). (b) PSA 2137, with inserted GES-5 (carbapenemase). (c) PSA 2138, with inserted GES-15. P values in the boxes represent the results from one-way ANOVA; P values are presented if between-group differences were present. The x-axis describes the treatment HSR [MIC (mg/L), % fT>MIC]. CAZ, Ceftazidime; CAZ-AVI, Ceftazidime/Avibactam; MEM, meropenem.
J Antimicrob Chemother

Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. [Abstract]

2020 Sep 1;75(9):2609-2615. PMID: 32591806
J Antimicrob Chemother

In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]

2020 Jul 1;75(7):1850-1858. PMID: 32154866

Ceftazidime pentahydrate purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]

The cumulative MIC distributions of Cefepime/Taniborbactam, Ceftazidime/Avibactam and comparator Meropenem for 500 tested isolates. The MICs of cefepime and Cefepime/Taniborbactam shown in the figure were tested by the broth microdilution method. The MICs of Meropenem shown in the figure were tested by the agar dilution method. SS, susceptible to all tested β-lactams. SS-P. aeruginosa, meropenem-susceptible P. aeruginosa. Nine IMP producers included three blaIMP-producing P. aeruginosa.
AMB Express

Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]

2024 Dec 24;14(1):141. PMID: 39718732

Ceftazidime pentahydrate purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]

Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.
Infect Drug Resist

2026 May 8;19.
Eur J Clin Microbiol Infect Dis

Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]

2025 Sep 29. PMID: 41023358
Eur J Clin Microbiol Infect Dis

Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa. [Abstract]

2025 Jun;44(6):1493-1500. PMID: 40056304
Adv Ther (Weinh)

2024 Jan 12.
Infect Drug Resist

In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China. [Abstract]

2021 Jun 30;14:2499-2507. PMID: 34234477
Infect Genet Evol

Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]

2025 Sep:133:105780. PMID: 40480594
J Antibiot (Tokyo)

Meropenem, Ceftazidime, and Polymyxin B combination therapy: a novel approach to combat antimicrobial resistance in MDR, XDR and PDR Escherichia coli. [Abstract]

2026 Feb 17. PMID: 41703045
J Antibiot (Tokyo)

Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new β-lactam/β-lactamase inhibitor combinations and on virulence of Escherichia coli isolates. [Abstract]

2023 Apr;76(4):225-235. PMID: 36726014
Res Sq

2026 Mar 10.
Res Sq

2026 Mar 9.
bioRxiv

2024 May 10.
bioRxiv

2024 Feb 9.
Biomed Pharmacother

The enhancement effect of small molecule Lyb24 reveals AzoR as a novel target of polymyxin B. [Abstract]

2023 Dec 31:169:115856. PMID: 37949698
Patent

US20200101105A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (78.54 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 29.17 mg/mL (45.82 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5707 mL

7.8536 mL

15.7072 mL

5 mM

0.3141 mL

1.5707 mL

3.1414 mL

10 mM

0.1571 mL

0.7854 mL

1.5707 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (3.93 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.93 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (398 KB)
- English - EN (398 KB)
- Français - FR (398 KB)
- Deutsch - DE (398 KB)
- Norwegian - NO (398 KB)
- Español - ES (398 KB)
- Swedish - SV (398 KB)
- Italian - IT (398 KB)
- Korean - KR (398 KB)
- Portuguese - PT (398 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Richards DM, et al. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Feb;29(2):105-61. [Content Brief]

[2]. Esmat Kamali, et al. In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms. BMC Microbiol. 2021 Dec 16;21(1):347. [Content Brief]

[3]. Qiuxia Lin, et al. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol. 2021 Feb 22;21(1):60. [Content Brief]

[4]. Shawn H MacVane, et al. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2014 Nov;58(11):7007-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.5707 mL	7.8536 mL	15.7072 mL	39.2680 mL
	5 mM	0.3141 mL	1.5707 mL	3.1414 mL	7.8536 mL
	10 mM	0.1571 mL	0.7854 mL	1.5707 mL	3.9268 mL
	15 mM	0.1047 mL	0.5236 mL	1.0471 mL	2.6179 mL
	20 mM	0.0785 mL	0.3927 mL	0.7854 mL	1.9634 mL
	25 mM	0.0628 mL	0.3141 mL	0.6283 mL	1.5707 mL
	30 mM	0.0524 mL	0.2618 mL	0.5236 mL	1.3089 mL
	40 mM	0.0393 mL	0.1963 mL	0.3927 mL	0.9817 mL
DMSO	50 mM	0.0314 mL	0.1571 mL	0.3141 mL	0.7854 mL
DMSO	60 mM	0.0262 mL	0.1309 mL	0.2618 mL	0.6545 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Ceftazidime pentahydrate

46 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ceftazidime pentahydrate

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Ceftazidime pentahydrate

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (46)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ceftazidime pentahydrate

Antibacterial Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Ceftazidime pentahydrate

Alle Beta-lactamase Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (46)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ceftazidime pentahydrate Related Classifications

HY-B0593A Related Classifications